Stem Cells in Oncology: Emerging Targets for Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 91
Special Issue Editors
Interests: leukemia stem cells; acute myeloid leukemia; chronic myeloid leukemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer treatment is a challenging task; thus, current therapeutics must be improved in order to achieve better outcomes. Understanding tumorigenesis would aid in the development of drugs for cancer treatment; however, the resistance developed by cancer cells after cancer therapies must be overcome. A distinguishing characteristic of cancer stem cells (CSCs) is that they cause relapse in solid as well as liquid tumors after remission, and recent studies have shown that CSCs can develop resistance against the cancer immunotherapy. CSCs are generally present in all types of tumors and divide and give rise to the other CSCs and tumor cells, which are less proliferative, less metastatic, and more differentiated. CSCs exhibit a remarkable capacity to initiate, propagate and spread malignant disease, also showing enhanced therapy resistance and being associated with disease relapse. Understanding the mechanisms implicated in the formation, self-renewal, quiescence, and adaptability of CSCs would enable the development of a multidirectional strategy for targeting and eradicating cancer stem cells. Cancer cells are heterogeneous due to genetic and epigenetic changes, and exhibit diverse patterns of gene expression and behavior. The specific molecules present on the surface of CSCs are known as biomarkers, and they distinguish CSCs from cancer cells. Intrinsic stem cell signals (Notch, Hedgehog, Wnt) interact with oncogenic signals (NF-Kβ, JAK-STAT, TGF/SMAD, PI3K/AKT/mTOR) to enhance the survival and self-renewal of CSCs. CSCs interact with tumor microenvironments in a reciprocal manner, thus playing a significant role in the development of cancer. The bidirectional communication provided by complex signaling facilitates immune evasion, metabolic adaptability, quiescence, and resistance of CSCs to cancer treatments. The unique characteristics of CSCs make them vulnerable to targeted therapy, but the biological function of most cancer cell biomarkers is not understood. These biomarkers aid in the prognosis and diagnosis of cancer, and can be employed as a useful target in immunotherapy in order to eliminate cancer. Targeting intrinsic cellular signaling pathways and metabolism is the key to eliminating CSCs. A comprehensive understanding of the interaction between the tumor microenvironment and CSCs would enable CSCs to be targeted, inhibiting stemness and quiescence, overcoming treatment resistance, and increasing immune sensitivity. Ongoing preclinical and clinical investigations have shown that targeting CSCs in conjugation with chemotherapy and immunological treatments improves sensitivity and provides a positive outcome. Eradicating CSCs requires acceptable and unique targets to be found via multidirectional means.
Dr. Ling Li
Dr. Umesh P Yadav
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer stem cells (CSCs)
- tumor microenvironment (TME)
- targeted therapy
- treatment resistance
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
